Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

BACKGROUND: Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking. PATIENTS AND METHODS: We performed an international, multicenter observational study to confirm sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fessas, Petros, Kaseb, Ahmed, Wang, Yinghong, Saeed, Anwaar, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Rafeh Naqash, Abdul, Muzaffar, Mahvish, Navaid, Musharraf, Khan, Uqba, Lee, ChiehJu, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Nimkar, Neil, Bettinger, Dominik, Benevento, Francesca, Hildebrand, Hannah, Pressiani, Tiziana, Abugabal, Yehia I, Personeni, Nicola, Huang, Yi-Hsiang, Rimassa, Lorenza, Ang, Celina, Marron, Thomas, Pinato, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462152/
https://www.ncbi.nlm.nih.gov/pubmed/32868393
http://dx.doi.org/10.1136/jitc-2020-001033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462152/
https://www.ncbi.nlm.nih.gov/pubmed/32868393
http://dx.doi.org/10.1136/jitc-2020-001033

Ejemplares similares